Hatch, Harkin Call For Withdrawal of NDI Draft Guidance
This article was originally published in The Tan Sheet
Executive Summary
Sens. Hatch and Harkin ask FDA to craft a new document to replace the current NDI notification draft guidance, recommending the agency “provide needed clarification” on what constitutes an NDI.
You may also be interested in...
Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry
More than four years after beginning to revise its widely criticized initial draft guidance on NDI notifications, FDA on Aug. 11 released a second draft. "I think it is reflective of a new effort by the agency to have a dialogue with the industry," says Steve Mister, president and CEO of the Council for Responsible Nutrition.
CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals
FDA’s position “is neither scientifically justified, logical nor in the interest of the public health,” CRN argues, asking FDA to reverse its position on synthetic botanicals outside the agency’s revision of the NDI draft guidance.
CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals
FDA’s position “is neither scientifically justified, logical nor in the interest of the public health,” CRN argues, asking FDA to reverse its position on synthetic botanicals outside the agency’s revision of the NDI draft guidance.